Abbott’s Minimally-Invasive Aortic Valve Implant Approved

The FDA has approved Abbott’s Navitor, a minimally-invasive transcatheter aortic valve implant (TAVI) device for treatment of severe aortic stenosis in patients at high risk for open-heart surgery.

The device features a fabric cuff to reduce or eliminate the backflow of blood around the valve frame and has leaflets within the native valve to help improve access to coronary arteries for future procedures.

Aortic stenosis is a narrowing of aortic valve's opening that restricts blood flow and can lead to heart failure and death if left untreated.

The Navitor device received a CE mark in 2021.